Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people aged 12 and over have been revised. It is anticipated that the appraisal will begin in late-August 2023 when we will write to you about how you can get involved.